BR9906600A - Forma de dosagem oral sólida compreendendo uma combinação de metformina e glibenclamida - Google Patents

Forma de dosagem oral sólida compreendendo uma combinação de metformina e glibenclamida

Info

Publication number
BR9906600A
BR9906600A BR9906600-9A BR9906600A BR9906600A BR 9906600 A BR9906600 A BR 9906600A BR 9906600 A BR9906600 A BR 9906600A BR 9906600 A BR9906600 A BR 9906600A
Authority
BR
Brazil
Prior art keywords
metformin
combination
dosage form
oral dosage
solid oral
Prior art date
Application number
BR9906600-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Yves Bonhomme
Geoffrey Nicholson
Gillian Cave
Sarah J Nicholson
Original Assignee
Lipha
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8235441&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9906600(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lipha filed Critical Lipha
Publication of BR9906600A publication Critical patent/BR9906600A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9906600-9A 1998-07-15 1999-07-12 Forma de dosagem oral sólida compreendendo uma combinação de metformina e glibenclamida BR9906600A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98401781A EP0974356B1 (en) 1998-07-15 1998-07-15 Tablets comprising a combination of metformin and glibenclamide
PCT/EP1999/005571 WO2000003742A2 (en) 1998-07-15 1999-07-12 Solid oral dosage form comprising a combination of metformin and glibenclamide

Publications (1)

Publication Number Publication Date
BR9906600A true BR9906600A (pt) 2000-07-18

Family

ID=8235441

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9906600-9A BR9906600A (pt) 1998-07-15 1999-07-12 Forma de dosagem oral sólida compreendendo uma combinação de metformina e glibenclamida

Country Status (27)

Country Link
US (2) US6303146B1 (enExample)
EP (4) EP0974356B1 (enExample)
JP (2) JP2002520371A (enExample)
KR (2) KR20040053177A (enExample)
CN (2) CN1146427C (enExample)
AP (1) AP1450A (enExample)
AR (2) AR013052A1 (enExample)
AT (1) ATE250418T1 (enExample)
AU (2) AU753604B2 (enExample)
BR (1) BR9906600A (enExample)
CA (1) CA2303537C (enExample)
DE (1) DE69818444T2 (enExample)
DK (1) DK0974356T3 (enExample)
DZ (1) DZ2846A1 (enExample)
ES (1) ES2206868T3 (enExample)
ID (1) ID25784A (enExample)
MA (1) MA24930A1 (enExample)
MY (1) MY129552A (enExample)
NZ (1) NZ503248A (enExample)
OA (1) OA11400A (enExample)
PT (1) PT974356E (enExample)
RU (2) RU2286788C2 (enExample)
SI (1) SI0974356T1 (enExample)
TW (2) TWI245632B (enExample)
UY (1) UY25611A1 (enExample)
WO (1) WO2000003742A2 (enExample)
ZA (1) ZA200001159B (enExample)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
ATE390140T1 (de) * 1999-11-03 2008-04-15 Bristol Myers Squibb Co Arzneimittel, umfassend eine kombination aus metformin und glibenclamide
US6586438B2 (en) * 1999-11-03 2003-07-01 Bristol-Myers Squibb Co. Antidiabetic formulation and method
US20010036479A1 (en) 2000-01-14 2001-11-01 Gillian Cave Glyburide composition
FR2816840B1 (fr) 2000-11-17 2004-04-09 Flamel Tech Sa Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
FR2816841B1 (fr) * 2000-11-22 2004-02-06 Lipha Nouvelles compositions pharmaceutiques a action antidiabetique et leur procede de preparation
US7964216B2 (en) * 2001-01-12 2011-06-21 Sun Pharma Advanced Research Company Limited Spaced drug delivery system
FR2825023B1 (fr) * 2001-05-23 2005-04-15 Flamel Tech Sa Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
US20050271737A1 (en) * 2001-06-07 2005-12-08 Chinea Vanessa I Application of a bioactive agent to a substrate
US7767249B2 (en) * 2001-06-07 2010-08-03 Hewlett-Packard Development Company, L.P. Preparation of nanoparticles
US8206753B2 (en) * 2001-06-20 2012-06-26 Metaproteomics, Llc Anti-inflammatory botanical products for the treatment of metabolic syndrome and diabetes
ATE378054T1 (de) * 2001-07-30 2007-11-15 Mitsubishi Pharma Corp Mittel zu linderung von hyperglykämie nach dem essen
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
US7183321B2 (en) * 2001-12-17 2007-02-27 Bristol-Myers Squibb Company Antidiabetic formulation and method
EP1482919B1 (en) * 2002-01-25 2007-05-02 Laboratorios Silanes, S.A. de C.V. Pharmaceutical composition that is used to control blood glucose in patients with type 2 diabetes
MXPA04008164A (es) * 2002-02-21 2005-05-17 Biovail Lab Inc Formas de dosificacion de liberacion controlada.
US20030187074A1 (en) * 2002-03-04 2003-10-02 Javed Hussain Oral compositions for treatment of diabetes
US20030219482A1 (en) * 2002-03-21 2003-11-27 Chaudhari Sunil Sudhakar Multiparticulate compositions for once-a-day administration
IL164221A0 (en) 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
ES2320438T7 (es) 2002-04-09 2013-02-14 Flamel Technologies Formulación farmaceútica oral de suspensión acuosa de microcápsulas que permiten la liberación modificada de principio(s) activo(s)
PL376577A1 (pl) 2002-06-17 2006-01-09 Themis Laboratories Private Limited Wielowarstwowe tabletki zawierające tiazolidinedion i biguanidy oraz metody ich wytwarzania
US7445796B2 (en) * 2002-08-19 2008-11-04 L. Perrigo Company Pharmaceutically active particles of a monomodal particle size distribution and method
WO2004045622A1 (en) * 2002-11-15 2004-06-03 Ranbaxy Laboratories Limited Pharmaceutical dosage forms of biguanide-sulfonylurea combinations
FR2853831A1 (fr) * 2003-03-05 2004-10-22 Usv Ltd Forme posologique solide a usage oral de metformine et de glyburide et son procede de preparation
TW200507875A (en) * 2003-04-15 2005-03-01 Chugai Pharmaceutical Co Ltd Remedy for diabetes
US20060121108A1 (en) * 2004-12-02 2006-06-08 Prasad C K System and method for producing a directly compressible, high-potency formulation of metformin hydrochloride
CN100341495C (zh) * 2004-12-29 2007-10-10 三九医药股份有限公司 格列本脲固体分散体、口服组合物及其制备方法
KR100760430B1 (ko) * 2004-12-31 2007-10-04 한미약품 주식회사 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
UY29445A1 (es) * 2005-03-30 2006-10-02 Generex Pharm Inc Composiciones para la transmisión transmucosa oral de la metformina
US8529537B2 (en) * 2005-08-05 2013-09-10 Kimberly-Clark Worldwide, Inc. Absorbent article with enclosures
MXPA05009633A (es) * 2005-09-08 2007-03-07 Silanes Sa De Cv Lab Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada.
CA2654661C (en) 2006-06-26 2012-10-23 Amgen Inc. Compositions comprising modified lcat and use thereof for treating atherosclerosis
WO2008062273A2 (en) * 2006-11-20 2008-05-29 Cadila Pharmaceuticals Limited Solid oral dosage form having antidiabetic drug combination
CN101801351B (zh) 2007-07-19 2012-12-12 武田药品工业株式会社 包含阿格列汀和盐酸二甲双胍的固体制剂
ES2559353T3 (es) 2007-07-26 2016-02-11 Amgen, Inc Enzimas lecitina-colesterol aciltransferasa modificadas
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
WO2011135106A1 (es) * 2010-04-26 2011-11-03 Smart Pharma Solutions, S.L Granulado altamente dispersable para la preparación de formulaciones de sustancias activas de altas dosis y procedimiento de obtención del mismo
RU2451506C1 (ru) 2011-06-02 2012-05-27 Сергей Юрьевич Лешков Комбинация для лечения сахарного диабета и его осложнений
CA2858572C (en) 2011-12-08 2023-01-17 Amgen Inc. Human lcat antigen binding proteins and their use in therapy
CA2859174C (en) * 2011-12-12 2019-03-05 Orbis Biosciences, Inc. Sustained release particle formulations
CN104127424A (zh) * 2014-07-30 2014-11-05 沈阳药科大学 格列本脲衍生物及其制备方法和应用
CN105030793A (zh) * 2015-08-25 2015-11-11 瑞阳制药有限公司 二甲双胍格列本脲胶囊及其制备方法
WO2019070109A1 (es) * 2017-10-03 2019-04-11 Infinite Clinical Research International, S.A. De C.V. Triconjugado para el tratamiento de diabetes mellitus
EP4141008A4 (en) 2020-04-01 2024-04-17 Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. PHARMACEUTICALLY ACCEPTABLE ACID SALT OF GLP-1 RECEPTOR AGONIST FREE BASE, AND PREPARATION METHOD THEREFOR
EP4130005A4 (en) 2020-04-01 2024-04-24 Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. CRYSTALLINE FORM A OF A GLP-1 RECEPTOR AGONIST AND METHOD OF MANUFACTURING THEREOF
KR102484756B1 (ko) * 2020-11-13 2023-01-06 한국생산기술연구원 용해성 증대 및 취급용이성을 갖는 파우더 배지의 과립화 방법
CN113143940A (zh) * 2020-12-30 2021-07-23 成都恒瑞制药有限公司 一种抗糖尿病药物组合物的制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE362704C (de) * 1921-08-09 1922-11-02 Naamlooze Vennootschap Interna Vorrichtung zum Senken einer Last, insbesondere eines Rettungsbootes
US3174901A (en) 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
DE2348334C2 (de) 1973-09-26 1982-11-11 Boehringer Mannheim Gmbh, 6800 Mannheim Neue Zubereitungsform des N-4-[2-(5-Chlor-2-methoxybenzamido)äthyl]- phenyl-sulfonyl-N'-cyclohexylharnstoffs
US4060634A (en) * 1973-09-26 1977-11-29 Boehringer Mannheim G.M.B.H. Rapidly resorbable glibenclamide
US4916163A (en) 1985-06-04 1990-04-10 The Upjohn Company Spray-dried lactose formulation of micronized glyburide
DE3833439A1 (de) 1988-10-01 1991-09-12 Hoechst Ag Verfahren zur mikronisierung von glibenclamid
IE63463B1 (en) * 1989-02-06 1995-04-19 Zeneca Ltd Phenylsulphone derivatives
GB9016978D0 (en) * 1990-08-02 1990-09-19 Ici Plc Acetamide derivatives
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
DE4323636A1 (de) 1993-07-15 1995-01-19 Hoechst Ag Arzneistoffzubereitungen aus umhüllten, schwerstwasserlöslichen Arzneistoffen für Inhalationsarzneiformen und Verfahren zu ihrer Herstellung
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
IT1276130B1 (it) * 1995-11-14 1997-10-27 Gentili Ist Spa Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo
EA003144B1 (ru) 1997-06-18 2003-02-27 Смитклайн Бичам Плс Способ лечения диабета тиазолидиндионом и метформином
US6544564B1 (en) * 2001-11-27 2003-04-08 Michael Donald Farley Cytotoxic pharmaceutical composition

Also Published As

Publication number Publication date
DK0974356T3 (da) 2003-10-27
TW200303208A (en) 2003-09-01
MY129552A (en) 2007-04-30
EP1435240A3 (en) 2009-08-12
RU2226396C2 (ru) 2004-04-10
US6303146B1 (en) 2001-10-16
AP2000001757A0 (en) 2000-03-31
AU753604B2 (en) 2002-10-24
UY25611A1 (es) 2000-08-21
KR20040053177A (ko) 2004-06-23
ZA200001159B (en) 2001-05-31
CA2303537C (en) 2005-12-06
WO2000003742A2 (en) 2000-01-27
ATE250418T1 (de) 2003-10-15
AP1450A (en) 2005-07-25
EP0974356B1 (en) 2003-09-24
CN1486698A (zh) 2004-04-07
SI0974356T1 (en) 2003-12-31
TWI245632B (en) 2005-12-21
AU2003261560A1 (en) 2005-05-26
CA2303537A1 (en) 2000-01-27
CN1275082A (zh) 2000-11-29
PT974356E (pt) 2004-02-27
AR013052A1 (es) 2000-11-22
USRE38629E1 (en) 2004-10-19
KR100478347B1 (ko) 2005-03-23
EP1435240A2 (en) 2004-07-07
JP2002520371A (ja) 2002-07-09
RU2286788C2 (ru) 2006-11-10
ES2206868T3 (es) 2004-05-16
JP2003292443A (ja) 2003-10-15
WO2000003742A3 (en) 2000-04-20
DE69818444D1 (de) 2003-10-30
OA11400A (en) 2004-04-08
DE69818444T2 (de) 2004-05-06
EP2269613A3 (en) 2012-10-17
RU2003126257A (ru) 2005-02-27
DZ2846A1 (fr) 2003-12-01
CN1146427C (zh) 2004-04-21
EP1011684A2 (en) 2000-06-28
AR065970A2 (es) 2009-07-15
EP2269613A2 (en) 2011-01-05
TW555560B (en) 2003-10-01
MA24930A1 (fr) 2000-04-01
AU5417999A (en) 2000-02-07
EP0974356A1 (en) 2000-01-26
ID25784A (id) 2000-11-02
KR20010030603A (ko) 2001-04-16
NZ503248A (en) 2002-09-27

Similar Documents

Publication Publication Date Title
BR9906600A (pt) Forma de dosagem oral sólida compreendendo uma combinação de metformina e glibenclamida
BR9912029A (pt) Compostos reacionais de amina compreendendo um ou mais ingredientes ativos
BR9915755A (pt) Anti-inflamátorio não-esteroidal
BR0213079A (pt) Forma de dosagem para o tratamento da diabetes mellitus
PT1193270E (pt) Pirrolobenzodiazepinas
ITMI991819A0 (it) Solfonilossime per fotoresist linea-1 di elevata sensibilita' ed eleva to spessore del resist
ITMI991316A0 (it) Composizioni farmaceutiche orali a rilascio modificato di mesalazina
HUP0003636A2 (hu) Analgetikum-kombináció
BR9607095A (pt) Composto composição farmacêutica e processos para fabricar e para administrar um composto
BR9910445A (pt) Preparação farmacêutica
ES2054843T3 (es) Compuesto organomineral de vanadilo, procedimiento para obtener tal compuesto, composicion farmaceutica que contiene dicho compuesto organomineral.
CO5070569A1 (es) Compuesto de aminoazol o una sal farmaceuticamente aceptable del mismo y medicamento que los contienen
BR9808140A (pt) Formulação unitária
KR960006915A (ko) 췌장염의 치료 조성물
BR0311193A (pt) Aduto de topiramato e cloridrato de tramadol e usos dos mesmos
ATE212225T1 (de) Injizierbare arzneizubereitung bestehend aus paracetamol
BR9912706A (pt) Composições farmacêuticas contendo ibuprofeno e domperidona
BR9704968A (pt) Processos para inibir o crescimento de células de mamíferos e a montagem de microtúbulos e para tratar uma doença que responde à inibição da mitose e composição farmacêutica
DE69812962D1 (de) Oral anzuwendende Arzneizubereitung enthaltend S-(3-Hydroxypropyl)-L-Cystein
ITMI950961A0 (it) Composizioni farmaceutiche contenenti gemfibrozil
ATE270551T1 (de) Kombinationspräparat aus 2-methylthiazolidin-2,4- dicarbonsäure und paracetamol
UY24780A1 (es) Composiciones farmacéuticas estabilizadas a base de quinupristina y dalfopristina y su preparación.
BR9808322A (pt) Processo para a preparação de 5-aminometil-2-cloropiridinas
PT1399142E (pt) Utilizacao de acetil-l-carnitina em associacao com biotina para o tratamento de doentes com diabetes mellitus insulino-resistente do tipo 2
AR023668A1 (es) Nuevos derivados de benzoilguanidina con ventajosas propiedades, procedimiento para su preparacion y su utilizacion en la preparacion de medicamentos

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE O MESMO NAO ATENDE AOS ESTABELECIDO NOS ARTIGOS 8O E 13, E 25 DA LPI - LEI 9279/96

B12B Appeal against refusal [chapter 12.2 patent gazette]
B15G Petition not considered as such [chapter 15.7 patent gazette]

Free format text: DESCONHECIDA DA PETICAO NO 020110110801/RJ DE 27/10/2011, O PEDIDO DE ALTERACAO DE NOME E SEDE POR AUSENCIA DE FUNDAMENTACAO LEGAL, UMA VEZ QUE O PEDIDO FOI INDEFERIDO CONFORME PUBLICADO NA RPI 2040 DE 09/02/2010.

B25H Request for change of headquarter rejected

Owner name: LIPHA (FR)

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08H Application fees: decision cancelled [chapter 8.8 patent gazette]